Top Markets
Coin of the day
Kailera Therapeutics, Inc. Kailera Therapeutics, Inc.

Kailera Therapeutics, Inc.

KLRA
Rank in Stocks #5874
Kailera Therapeutics is a biopharmaceutical company currently advancing through... Kailera Therapeutics is a biopharmaceutical company currently advancing through its clinical development stage, dedicated to cultivating a varied portfolio of cutting-edge treatments. These therapeutics are specifically engineered to tackle obesity and its associated metabolic disorders. The company distinguishes itself through its focus on innovative methodologies, offering both injectable and orally administered formulations for sustainable weight management. Its most advanced candidate is a groundbreaking dual-action gut hormone receptor agonist, which has reported encouraging outcomes in its initial clinical investigations.
Share Price
$18.35
Last synced: 2026-08-26
Market Cap
$2.38B
Change (1 day)
3.35%
Change (1 year)
-
Country
US
Trade Kailera Therapeutics, Inc. (KLRA)

Category

P/B ratio for Kailera Therapeutics, Inc. (KLRA)
P/B ratio as of 2026 TTM: 0
According to Kailera Therapeutics, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Kailera Therapeutics, Inc. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
3.7087 -
US
- -
CH